SS Innovations Names Dr. Fredric Moll Vice Chairman
SS Innovations International, Inc. (OTC: SSII), dedicated to reshaping how surgical robotics are designed and used, has appointed Dr. Fredric Moll to its Board of Directors as Vice Chairman. Often described as the “father of surgical robotics,” Dr. Moll is best known for his pivotal role in the creation and development of the da Vinci surgical system. He brings hard-won expertise, a builder’s mindset, and a long view of where surgical technology can and should go next.
Dr. Fredric Moll’s Track Record in Medical Robotics
Until March 2023, Dr. Moll served as Chief Development Officer at Johnson & Johnson Medical Devices Companies, where he focused on advancing next-generation tools for the operating room. His earlier work as co-founder and CEO of Auris Health, Inc.—later acquired by Johnson & Johnson—cemented his reputation as a leader who can take a concept from early design to real-world use. In addition to investing in SS Innovations, he has served on multiple medical technology boards, including Shockwave Medical, where he remained a director until its recent acquisition. The throughline is clear: he has repeatedly helped new ideas reach clinicians and patients.
A Strategic Voice at a Pivotal Moment
SS Innovations Chairman and CEO, Dr. Sudhir Srivastava, shared that Dr. Moll’s guidance arrives at a critical time as the company enters a new phase of global growth. Drawing on decades spent building and refining surgical platforms, Dr. Moll’s perspective is expected to help the company stay focused on what matters most in robotic surgery: reliability, usability, and outcomes. It’s leadership with a practical edge—shaped in the lab, the boardroom, and the operating room.
Aligned on Access, Cost, and Capability
Dr. Moll expressed strong support for SS Innovations’ mission to extend the benefits of robotic surgery to a wider audience. That goal aligns with the company’s focus on global access: make advanced capabilities available at a price point that removes a key barrier to adoption. By designing for affordability alongside performance, SS Innovations aims to meet health systems where they are—so more patients and clinicians can benefit, not just a few.
SSI Mantra 3: A Milestone System
The launch of the SSI Mantra 3 earlier this year marked a major step forward for the company. This advanced surgical robotic system is built to support a range of specialties, including gynecology, cardiothoracic surgery, and urology. Its feature set is designed to enhance surgeon collaboration, streamline workflows, and help teams execute complex procedures more safely and efficiently. In short: it’s engineered for the teamwork and precision modern surgery demands.
Regulatory Progress and Next Steps
SS Innovations is moving through the FDA review process for the SSI Mantra 3, with expectations to receive approval by 2025. Achieving this milestone would open the door to broader clinical use and greater impact across the medical community, reinforcing the company’s momentum.
About SS Innovations International, Inc.
SS Innovations International, Inc. (OTC: SSII) focuses on making robotic surgery both accessible and affordable worldwide. In addition to the SSI Mantra system, the company offers the “SSi Mudra,” a versatile portfolio of surgical instruments. Headquartered in India, SS Innovations is working to bring its solutions to more hospitals and surgical teams globally—pairing advanced engineering with practical value.
Frequently Asked Questions
Why does Dr. Fredric Moll’s appointment matter?
As Vice Chairman, Dr. Moll brings decades of hands-on experience in building surgical robotics, including his foundational work on the da Vinci system. His leadership is expected to guide SS Innovations as it scales and innovates.
What technologies is SS Innovations focused on right now?
The company is advancing the SSI Mantra surgical robotic system and offers the “SSi Mudra” line of surgical instruments, with an emphasis on combining capability with affordability.
When does SS Innovations expect FDA approval for SSI Mantra 3?
The company anticipates receiving FDA approval to market the SSI Mantra 3 in late 2025, a step that would support wider clinical adoption.
How does the SSI Mantra 3 aim to improve surgery?
SSI Mantra 3 is designed to enhance safety, efficiency, and collaboration among surgical teams across specialties such as gynecology, cardiothoracic surgery, and urology.
Where is SS Innovations based, and where is it headed?
SS Innovations is headquartered in India and is focused on growing its global presence with user-friendly, cost-conscious robotic solutions.
